LogicBio Therapeutics (OTCMKTS:LOGC) Shares Climb 0.3% – Here’s What Happened

Shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) were up 0.3% during trading on Monday. The company traded as high as $15.35 and last traded at $15.14. 154,009 shares were traded during trading, an increase of 60% from the average daily volume of 95,956 shares. The stock had previously closed at $15.10.

LogicBio Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The business has a 50-day moving average price of $13.80 and a 200 day moving average price of $10.69. The stock has a market capitalization of $688.69 million, a P/E ratio of -20.63 and a beta of 2.04.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $33.60 million during the quarter, compared to the consensus estimate of $33.60 million.

About LogicBio Therapeutics

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing therapies for patients with severe genetic diseases. The company’s research centered on its GeneRide platform, an approach designed to support the targeted insertion of therapeutic genes into the genome and potentially provide durable treatment after a single administration.

LogicBio’s lead investigational program was LB-001, an experimental gene therapy for methylmalonic acidemia, a rare inherited metabolic disorder that primarily affects children.